New combo aims to shrink rectal tumors before surgery
NCT ID NCT07509424
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a short course of radiation followed by three drugs (disitamab vedotin, sintilimab, and capecitabine) can completely eliminate tumors in people with advanced HER2-positive rectal cancer. About 29 adults aged 18-75 will receive the treatment before surgery. The goal is to see how many patients have no cancer left at the time of surgery or on follow-up scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••